To explore the efficacy and safety of Tongxinluo Capsules in treating coronary heart disease with angina pectoris.Methods:A randomized，double-blind，placebo-controlled，multi-center clinical trial was conducted in 126 subjects，who were selected from March 2017 to February 2018，and were randomly divided into a control group and an observation group according to random number table method，with 63 cases in each group.All the subjects were given basic treatment.The observation group was given Tongxinluo Capsules and the control group was given placebo(Tongxinluo Capsule simulator)，3 capsules per time，twice a day for 2 weeks.Endothelial function，inflammatory factors，blood lipid index were analyzed to evaluate the efficacy after treatment，and the safety was observed and compared.Results:1)Full analysis set(FAS)analysis showed that there was no significant difference in TC，TG and HDL-C between the 2 groups before treatment(P>0.05).After treatment，TC and TG decreased significantly，and HDL-C increased significantly(P<0.05).After treatment，the above indexes in the observation group were significantly better than those in the control group(P<0.05).The per protocol set(PPS)and the FAS result were similar.2)FAS analysis showed that there was no significant difference in TNF-α，CRP and IL-6 between the 2 groups before treatment(P>0.05).After treatment，the above indexes of the 2 groups decreased significantly(P<0.05).After treatment，the above indexes of the observation group were significantly better than those of the control group(P<0.05).The PPS and FAS results were similar.3)FAS analysis showed that there was no significant difference in NO，ET-1 and TXB2 between the 2 groups before treatment(P>0.05).After treatment，ET-1 and TXB2 decreased significantly and NO increased significantly(P<0.05).After treatment，the above indexes in the observation group were significantly better than those in the control group(P<0.05).The PPS and FAS results were similar.4)FAS analysis showed that the effective rate and total effective rate of the observation group were significantly higher than those of the control group(P<0.05)，and the PPS and FAS results were similar.5)FAS analysis showed that the adverse reaction rate was 6.34% in the control group and 4.76% in observation group.There was no significant difference between the 2 groups(P>0.05).The PPS and FAS results were similar.Conclusion:Tongxinluo Capsules can inhibit angina inflammation，improve vascular endothelial function，improve curative effect，and has high safety.